Understanding how mitochondria release factors that trigger cell death in cancer
Elucidating the structural basis of mitochondrial outer membrane permeabilization in apoptosis
['FUNDING_R01'] · UNIV OF ARKANSAS FOR MED SCIS · NIH-10898597
This study is looking at how a protein called BAK helps trigger cell death in cancer, and by understanding how it works, the researchers hope to find better ways to make cancer cells die and improve treatment for patients.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | UNIV OF ARKANSAS FOR MED SCIS (nih funded) |
| Locations | 1 site (LITTLE ROCK, UNITED STATES) |
| Trial ID | NIH-10898597 on ClinicalTrials.gov |
What this research studies
This research investigates the process of mitochondrial apoptosis, which is a type of programmed cell death that can be disrupted in cancer. The focus is on a specific protein called BAK, which plays a crucial role in the release of factors from mitochondria that activate cell death pathways. By using advanced techniques in structural biology, biophysics, and cell biology, the researchers aim to clarify how BAK is activated and how it interacts with cell membranes. This understanding could lead to new strategies for promoting cell death in cancer cells, potentially improving treatment outcomes.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients with cancers that are resistant to current treatments, particularly those involving the BCL-2 protein family.
Not a fit: Patients with non-cancerous conditions or those whose cancers are not influenced by mitochondrial apoptosis may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new therapies that effectively induce cancer cell death, improving survival rates for patients with cancer.
How similar studies have performed: Other research has shown promising results in targeting apoptosis pathways in cancer, suggesting that this approach could be effective.
Where this research is happening
LITTLE ROCK, UNITED STATES
- UNIV OF ARKANSAS FOR MED SCIS — LITTLE ROCK, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: MOLDOVEANU, TUDOR — UNIV OF ARKANSAS FOR MED SCIS
- Study coordinator: MOLDOVEANU, TUDOR
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.